Cost‐utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide
Authors' conclusion
This study shows that, using SEMA as a reference, the annual costs for TIRZ 10 and 15 mg are $1573.00-$1967.16 and $1576.54-$2133.96, respectively, for patients with type 2 diabetes in China.
Study context
- Population
- Patients with T2D in China; cohort and efficacy data from the SURPASS-2 trial
- Comparison
- Tirzepatide 5, 10, 15 mg vs semaglutide 1 mg
- Outcome
- Most matchable price of TIRZ vs SEMA
Methodological detailslifetime simulation, binary search, Chinese healthcare provider's perspective, univariate sensitivity analysis, probabilistic sensitivity analysis, scenario analysis
- Lifetime simulation
- Binary search
- Chinese healthcare provider's perspective
- Univariate sensitivity analysis
- Probabilistic sensitivity analysis
- Scenario analysis
Main finding
As reported in the abstract
Cost range for TIRZ (most matchable price)
Tirzepatide (TIRZ) 5 mg
$1628.61-$1846.23
TIRZ 10 mg
$1738.40-$2140.95
TIRZ 15 mg
$1800.30-$2430.81
Further findings
Quality-adjusted life years · lifetime simulation
| Outcome | TIRZ 5 mg | TIRZ 10 mg | TIRZ 15 mg | SEMA 1 mg |
|---|---|---|---|---|
| Cost range for TIRZ after adjustment in univariate sensitivity analysis | $1542.68-$1757.57 | $1573.00-$1967.16 | $1576.54-$2133.96 | — not stated in the abstract |
— not stated in the abstract
Cost range for TIRZ after adjustment in univariate sensitivity analysis
- Cost intervals validated by probabilistic sensitivity and scenario analyses, except for TIRZ 5 mg
Original publication
Cost‐utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide. Diabetes Obes Metab. Published 13 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →